These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 7586901)

  • 1. Clinical pharmacokinetics of various topical ophthalmic delivery systems.
    Frangie JP
    Clin Pharmacokinet; 1995 Aug; 29(2):130-8. PubMed ID: 7586901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Undefined role of mucus as a barrier in ocular drug delivery.
    Ruponen M; Urtti A
    Eur J Pharm Biopharm; 2015 Oct; 96():442-6. PubMed ID: 25770770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation.
    Akpek EK; Vittitow J; Verhoeven RS; Brubaker K; Amar T; Powell KD; Boyer JL; Crean C
    J Ocul Pharmacol Ther; 2009 Oct; 25(5):433-9. PubMed ID: 19857105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive insight on ocular pharmacokinetics.
    Agrahari V; Mandal A; Agrahari V; Trinh HM; Joseph M; Ray A; Hadji H; Mitra R; Pal D; Mitra AK
    Drug Deliv Transl Res; 2016 Dec; 6(6):735-754. PubMed ID: 27798766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prolonged exposure to loteprednol etabonate in human tear fluid and rabbit ocular tissues following topical ocular administration of Lotemax gel, 0.5%.
    Glogowski S; Lowe E; Siou-Mermet R; Ong T; Richardson M
    J Ocul Pharmacol Ther; 2014 Feb; 30(1):66-73. PubMed ID: 24325539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenylboronic-Acid-Based Polymeric Micelles for Mucoadhesive Anterior Segment Ocular Drug Delivery.
    Prosperi-Porta G; Kedzior S; Muirhead B; Sheardown H
    Biomacromolecules; 2016 Apr; 17(4):1449-57. PubMed ID: 26963738
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomes in topical ophthalmic drug delivery: an update.
    Agarwal R; Iezhitsa I; Agarwal P; Abdul Nasir NA; Razali N; Alyautdin R; Ismail NM
    Drug Deliv; 2016 May; 23(4):1075-91. PubMed ID: 25116511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular design for enhancement of ocular penetration.
    Shirasaki Y
    J Pharm Sci; 2008 Jul; 97(7):2462-96. PubMed ID: 17918725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New vehicle based on a microemulsion for topical ocular administration of dexamethasone.
    Fialho SL; da Silva-Cunha A
    Clin Exp Ophthalmol; 2004 Dec; 32(6):626-32. PubMed ID: 15575833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular pharmacokinetics in rabbits using a novel dual probe microdialysis technique.
    Macha S; Mitra AK
    Exp Eye Res; 2001 Mar; 72(3):289-99. PubMed ID: 11180978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Transcorneal drug delivery: prospects for the use of liposomes].
    Aliautdin RN; Iezhitsa IN; Agarval R
    Vestn Oftalmol; 2014; 130(4):117-22. PubMed ID: 25306734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraocular distribution of topically applied hydrophilic and lipophilic substances in rat eyes.
    Abdul Nasir NA; Agarwal P; Agarwal R; Iezhitsa I; Alyautdin R; Nukolova NN; Chekhonin VP; Mohd Ismail N
    Drug Deliv; 2016 Oct; 23(8):2765-2771. PubMed ID: 26289215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression, activity and pharmacokinetic impact of ocular transporters.
    Vellonen KS; Hellinen L; Mannermaa E; Ruponen M; Urtti A; Kidron H
    Adv Drug Deliv Rev; 2018 Feb; 126():3-22. PubMed ID: 29248478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid nanoparticles (SLN, NLC): Overcoming the anatomical and physiological barriers of the eye - Part I - Barriers and determining factors in ocular delivery.
    Sánchez-López E; Espina M; Doktorovova S; Souto EB; García ML
    Eur J Pharm Biopharm; 2017 Jan; 110():70-75. PubMed ID: 27789358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of ocular drug penetration.
    Sasaki H; Yamamura K; Mukai T; Nishida K; Nakamura J; Nakashima M; Ichikawa M
    Crit Rev Ther Drug Carrier Syst; 1999; 16(1):85-146. PubMed ID: 10099899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular delivery systems for topical application of anti-infective agents.
    Duxfield L; Sultana R; Wang R; Englebretsen V; Deo S; Rupenthal ID; Al-Kassas R
    Drug Dev Ind Pharm; 2016 Jan; 42(1):1-11. PubMed ID: 26325119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid lipid nanoparticles for ocular drug delivery.
    Seyfoddin A; Shaw J; Al-Kassas R
    Drug Deliv; 2010; 17(7):467-89. PubMed ID: 20491540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability.
    Gan L; Han S; Shen J; Zhu J; Zhu C; Zhang X; Gan Y
    Int J Pharm; 2010 Aug; 396(1-2):179-87. PubMed ID: 20558263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
    Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
    Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Modeling of Ocular Pharmacokinetics and Adverse Effects.
    Ghemtio L; Xhaard H; Urtti A; Kidron H
    Curr Pharm Des; 2016; 22(46):6928-6934. PubMed ID: 27669964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.